MCI-9042

DRUG2 trials

Sponsors

Tanabe Pharma Corporation

Conditions

Cerebral Infarction

Phase 3

Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS)

CompletedNCT00129805

Tanabe Pharma CorporationCerebral Infarction

Start: 2001-01-31End: 2004-09-30Updated: 2008-08-19

Effect of Sarpogrelate on Platelet Aggregation in Patients With Cerebral Infarction: Dose-responsive Clinical Pharmacology Study

CompletedNCT00147303

Tanabe Pharma CorporationCerebral Infarction

Start: 2004-04-30End: 2005-01-31Updated: 2015-04-10